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Tremendous advances have been made
in the past decades in characterizing
the autoantigens of the major autoim-
mune bullous skin diseases, which
provide a direct relationship among
distinct clinical phenotypes, the nature
and distribution of the targeted auto-
antigens, and the molecular mechan-
isms of the immune pathogenesis of
these disorders.
Pemphigus encompasses a group of
life-threatening autoimmune diseases
with extensive blistering of the mucous
membranes and the skin, that is char-
acterized by intraepidermal loss of
adhesion caused by autoantibodies
against components of desmosomes
that confer adhesion between epider-
mal keratinocytes. Anhalt et al. (1982)
were the first to provide direct evidence
that immunoglobulin G (IgG) autoanti-
bodies from pemphigus sera cause
epidermal loss of adhesion when in-
jected into neonatal mice. Amagaiet al.
(1991) successfully cloned the cDNA
encoding a 130 kDa protein that was
recognized specifically by pemphigus
sera and was identified as a novel
desmosomal adhesion protein, named
desmoglein 3 (Dsg 3). Stanley et al.
(1986) identified another desmosomal
cadherin, Dsg 1, which had many
structural homologies with Dsg 3 and
turned out to be the autoantigen of
pemphigus foliaceus, a related disorder
characterized by extensive superficial
erosions of the skin. Moreover,
Stanley and co-workers (Mahoney
et al., 1999) provided the pathogenic
explanation as to why distinct autoanti-
body profiles cause a distinct clinical
phenotype in pemphigus. The so-called
compensation hypothesis is based on
the concept that Dsg 1 and Dsg 3
compensate each other’s loss of func-
tion upon binding of pemphigus auto-
antibodies in tissues where they are
equally expressed. In pemphigus folia-
ceus, IgG against Dsg 1 causes super-
ficial cutaneous blisters because Dsg 1
is exclusively expressed in the stratum
granulosum of stratified squamous
epithelia and is thus not substituted by
Dsg 3. In pemphigus vulgaris, anti-Dsg
3 IgG autoantibodies cause suprabasi-
lar loss of adhesion of noncornified
squamous epithelia (that is mucous
membranes) where Dsg 3 is exclusively
expressed and cannot be substituted by
Dsg1.
The relevance of the adhesive func-
tion of desmosomal cadherins for epi-
dermal integrity was demonstrated by
Koch et al. (1997), who generated
Dsg3-deficient mice, which showed
blisters of the oral mucosa and snout
due to the loss of adhesion between
epidermal keratinocytes. Finally, a
most elegant study by Amagai et al.
(2000) showed that blistering due to a
loss of adhesive function of Dsg 1 is
also an inherent feature of bullous
impetigo and staphylococcal scalded
skin syndrome, two disorders that
are caused by Staphylococcus aureus
infection of the skin. Staphylococcal
exfoliative toxin is a serine protease
that specifically cleaves the extracellu-
lar portion of Dsg 1 that harbors
the major antigenic sites targeted
by pathogenic autoantibodies in
pemphigus.
Lymphatic tumors, drugs containing
thiols and nonthiol components, and
various infectious agents have all been
implicated as triggering factors in the
loss of immunological tolerance
against Dsg, leading to the etiopatho-
genesis of pemphigus. Diaz and col-
leagues suggested that an endemic
variant of pemphigus foliaceus, fogo
selvagem, which occurs in restricted
areas of central South America, may be
triggered by local factors such as
infections (Warren et al., 2000). They
reported a high prevalence of indivi-
duals with IgG antibodies against Dsg 1
in these restricted areas who later
developed full-blown fogo selvagem.
Immunologically, the patients’ autoan-
tibodies targeted epitopes of Dsg 1
(namely its N terminus) that were
different from the nonpathogenic epi-
topes (located in the C terminus of
Dsg1) found in the healthy residents of
this endemic area (Li et al., 2003).
These findings support the concept that
a shifted epitope recognition of human
autoantigens precedes the clinical out-
come of an overt autoimmune disease.
Ongoing research strongly suggests
that the production of autoantibodies is
tightly controlled by Dsg-specific auto-
aggressive T cells, which are critical for
the induction, perpetuation, and im-
mune surveillance of the autoimmune
response against Dsg 3 and Dsg 1
(reviewed in Hertl et al., 2006).
Immunobullous subepidermal blis-
tering diseases are characterized by
autoantibodies to cell–matrix adhesion
molecules of the dermal–epidermal
junction (DEJ). Stanley et al. (1981)
were the first to characterize a consti-
tuent of the DEJ as the target of
autoantibodies. They identified a
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230 kDa protein (BPAG1) labeled by
antibodies in serum of patients with
bullous pemphigoid (BP). Labib et al.
(1986) characterized BP180 (BPAG2)
as another autoantigen targeted by BP
autoantibodies. Cloning of the corre-
sponding cDNAs demonstrated BP230
to be a constituent of the hemidesmo-
somal plaque, whereas BP180 was
found to be a transmembrane hemi-
desmosomal glycoprotein and a mem-
ber of the collagen protein family, also
referred to as type XVII collagen
(Stanley et al., 1988; Diaz et al.,
1990; Giudice et al., 1992). Subse-
quently, BP180 was shown to be
cleaved from the keratinocyte cell sur-
face (Pas et al., 1997; Hirako et al.,
1998; Scha¨cke et al., 1998). This
shedding is mediated by disintegrin
and metalloprotease proteins (Franzke
et al., 2002).
Zone et al. (1990) were the first to
report that immunoglobulin A (IgA)
autoantibodies from patients with line-
ar IgA disease react with a 97 kDa
protein (LABD97) of the DEJ. Subse-
quently, Marinkovich et al. (1996)
identified a 120 kDa protein (LAD-1),
synthesized by keratinocytes as the
target of these IgA autoantibodies. On
the basis of biochemical studies and
peptide sequence analysis, it was de-
monstrated that LABD97 and LAD-1
represent portions of the BP180 ecto-
domain resulting from cleavage within
the membrane-proximal NC16A do-
main (Zone et al., 1998; Hirako et al.,
2003). In contrast to the majority of BP
sera, most LAD sera do not react with
this domain of BP180 (Zillikens et al.
1997, 2003).
In addition to BP and LAD, pemphi-
goid gestationis and lichen planus
pemphigoides are further diseases as-
sociated with an autoimmune response
to the immunodominant NC16A do-
main of BP180. Although in pemphi-
goid gestationis autoantibodies almost
exclusively react with the N-terminal
45 amino acids of this domain,
the immune response in lichen
planus pemphigoides focuses on the
C-terminal portion of NC16A (Zillikens
2003).
The fifth disease that may be asso-
ciated with autoantibodies to BP180
NC16A is mucous membrane pemphi-
goid. This is a heterogenous disease
with respect to clinical manifestation,
the isotype of the associated autoanti-
body, the side of skin split by 1 M NaCl
that is bound by the autoantibody, and
the specific target antigen(s) within the
DEJ (Chan et al., 2002). The best-
characterized autoantigens in mucous
membrane pemphigoid include BP180,
laminin 332, type VII collagen, and the
subunits of a6b4 integrin. Most mucous
membrane pemphigoid patients show
reactivity with BP180 (Bernard et al.,
1990). Domloge-Hultsch et al. (1992)
described a group of patients with IgG
autoantibodies against laminin 332
(previously referred to as laminin 5 or
epiligin).
More recently, a previously un-
known pemphigoid disease was re-
ported that is associated with
autoantibodies to a 200 kDa protein of
the lower lamina lucida (Zillikens
et al., 1996). By indirect IF microscopy
on 1 M NaCl-split skin, the autoantibo-
dies bind exclusively to the dermal
side. By immunoblotting, they label a
200 kDa protein extracted from dermis,
but do not react with epidermal con-
stituents. The characterization of this
autoantigen, which is different from
other known autoantigens of the DEJ,
awaits elucidation at the molecular
level (Dilling et al., 2007).
In 1984, Woodley et al. (1988)
characterized a 290 kDa dermal pro-
tein as the target of autoantibodies in
patients with epidermolysis bullosa
acquisita Subsequently, this antigen
was identified as type VII collagen.
Gammon et al. (1984) described NaCl
splitting of the DEJ leading to cleavage
within the lamina lucida. When this
1 M NaCl-split skin is used for indirect
IF microscopy, it facilitates rapid differ-
entiation between BP and epidermoly-
sis bullosa acquisita. In addition,
autoantibodies to BP230, plectin,
BP180, and a6b4 integrin bind to the
epidermal side of the split, whereas
those to laminin 332, p200, and both
type IV and type VII collagen label the
dermal side. Therefore, indirect IF
microscopy on 1 M NaCl-split skin is
used as an initial analysis before further
characterizing the specificity of pa-
tients’ autoantibodies by immunoblot-
ting, immunoprecipitation, or ELISA.
Dermatitis herpetiformis (DH) is a
chronic autoimmune bullous disease
characterized by chronic itchy lesions
of various morphology. Immunologi-
cally, granular IgA deposits in dermal
papillae are a hallmark of this disorder.
DH is tightly associated with gluten-
sensitive enteropathy (Katz et al., 1980)
and differs from linear IgA disease on
the basis of the different pattern of
tissue-bound IgA antibodies and the
different specificity of autoantibodies.
Dieterich et al. (1999) detected IgA
autoantibodies against tissue transglu-
taminase in the sera of patients with
DH. More recently, Sa´rdy et al. (2002)
showed that epidermal transglutami-
nase, which is highly homologous to
tissue transglutaminase, is the nominal
autoantigen of DH. This finding ex-
plains why the majority of—if not all—
patients with DH have cross-reactive
IgA autoantibodies against tissue trans-
glutaminase (which provide a reliable
serological marker for establishing the
diagnosis of DH).
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